ZYNE Zynerba Pharmaceuticals, Inc.

7.30
+0  (0%)
Previous Close 7.30
Open 7.30
Price To book 1.86
Market Cap 67.15M
Shares 9,199,000
Volume 112,586
Short Ratio 5.08
Av. Daily Volume 201,943

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
ZYN001
Fibromyalgia
Phase 2 to be initiated 2H 2017.
ZYN001
Peripheral Neuropathic Pain (PNP)
Phase 2 trial initiation announced January 3, 2017. Data are due late 1H 2017.
ZYN002
Fragile X syndrome
Phase 2 initiated September 2016. Data are due July or August 2017.
ZYN002
Osteoarthritis
Phase 2 dosing commenced August 2016. Data are due July or August 2017.
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures

Latest News

  1. Patterson Companies (PDCO) Q3 Earnings: What's in Store?
  2. Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
  3. Harry Boxer: These four momentum stocks are breaking out
  4. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
  6. Innovative Marijuana-Based Medicines In the Making
  7. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  8. Cannabis Drug Company Zynerba Is Gearing Up For A Big Summer
  9. Cannabis Stocks Do Not Trade on Earnings, Instead on Pipeline of Drugs
  10. Developer of cannabinoid patch seeking $50M from stock sale
  11. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
  12. Thursday’s Top Biopharma Movers
  13. Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  14. GNC Plummets, Mallinckrodt Regains Ground Ahead of Market's Open
  15. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
  16. Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
  17. Donald Trump On Weed Legalization: What’s In Store For Marijuana Stocks?
  18. Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 9.5%
  19. ZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  20. Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome